ArticleJournal of diabetes science and technology2025
Increased Glycemic Variability in Patients With Chronic Pancreatitis and Diabetes Compared to Type 2 Diabetes.
Article in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Continuous Glucose Monitoring Data Compression Using Peak-Nadir Encoding in Diabetes: Method Development and Evaluation.JMIR biomedical engineering · 2026Article
- Use of hybrid closed-loop insulin pump in pancreatogenic diabetes following necrotizing hemorrhagic pancreatitis: a case report.Frontiers in clinical diabetes and healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycemic variability in diabetes secondary to pancreatic diseases (pancreatic diabetes) remains unclear. We compared glycemic control and variability in patients with pancreatic diabetes and a matched group of individuals with type 2 diabetes using continuous glucose monitoring (CGM).
methodsWe included 30 patients with chronic pancreatitis and insulin-treated secondary diabetes and 30 individuals with insulin-treated type 2 diabetes (matched on HbA1c, age, and sex). Participants wore a blinded CGM for 20±2 days. Glycemic variability was assessed using coefficient of variation (CV), standard deviation (SD), mean amplitude of glycemic excursions (MAGE), and continuous overall net glycemic action (CONGA) at 1 and 2-hour intervals. Glycemic control was evaluated based on time spent in predefined glucose ranges: >250 mg/dL, 181 to 250 mg/dL, 70 to 180 mg/dL (target range), 54 to 69 mg/dL, and <54 mg/dL. CGM parameters were compared between groups.
resultsAll CGM-derived measures of glycemic variability (CV, SD, MAGE, CONGA1, and CONGA2) were significantly higher in patients with chronic pancreatitis and diabetes compared to individuals with type 2 diabetes (
conclusionPatients with pancreatic diabetes have higher glycemic variability than individuals with type 2 diabetes despite comparable levels of HbA1c.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.